Inogen Inc Stock Price, News & Analysis

Inogen, Inc. (NASDAQ: INGN) appointed Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022, succeeding interim CFO Mike Sergesketter. Nabil Shabshab, CEO, expressed confidence in Caltrider's proven experience in healthcare financial operations. Caltrider previously served as Vice President of Finance at Quidel Corporation. She aims to leverage Inogen's strong talent base and strategic plan for sustainable growth. The transition aims for smooth continuity as the company seeks to enhance its position in the respiratory care MedTech sector.

Inogen, Inc. (NASDAQ: INGN) reported Q4 2021 total revenue of $76.4 million, a 3.3% year-over-year increase. Domestic direct-to-consumer revenue rose 23.3% to $33.0 million, while rental revenue surged 39.4% to $13.0 million. Full-year revenue reached $358.0 million, up 16.1% from 2020. Adjusted EBITDA for Q4 was ($0.5 million) with a net loss of $22.9 million. Supply chain challenges, especially regarding semiconductor availability, are expected to impact operations in 2022. The company anticipates mid-single-digit revenue growth for the year, with negative EBITDA and operating losses projected for Q1 2022.

Inogen, Inc. (NASDAQ: INGN) will release its fourth quarter 2021 financial results after market close on February 24, 2022. A conference call is scheduled for 2:00 PM PT / 5:00 PM ET to discuss the results. Interested parties can listen by calling (877) 841-3961 for domestic and (201) 689-8589 for international callers. A replay will be available starting at 4:00 PM PT on the same day until March 10, 2022. More information is accessible via their Investor Relations website.

Inogen, Inc. (NASDAQ: INGN) announced preliminary Q4 2021 revenue between $75.9 million and $76.9 million, a 2.6% to 3.9% increase from Q4 2020. Full-year revenue for 2021 is expected to be between $357.5 million and $358.5 million, marking a 15.9% to 16.2% increase year-over-year. The revenue growth was supported by higher average selling prices and demand, despite challenges from semiconductor supply constraints. Inogen faces a potential halt in EU sales due to regulatory changes expected by May 2022.

Gelesis has appointed Ali Bauerlein to its Board of Directors as it prepares for a public listing. Bauerlein, with a successful track record in scaling companies, previously co-founded Inogen (NASDAQ: INGN) and led it to over $300M in revenue. Gelesis aims to expand the commercialization of its product Plenity, a weight management solution. The company is also moving forward with its merger with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR), with the registration statement approved by the SEC. The combined entity's shares will trade under the ticker GLS.

Inogen, Inc. (NASDAQ: INGN) announced the election of Elizabeth Mora as Board Chairperson, succeeding Heath Lukatch, who will remain on the Board. Ray Huggenberger is retiring from the Board after serving since 2008 but will transition to an advisory role. Mora, who joined the Board in May 2021, will also chair the Compliance Committee. The Board has been reduced to seven members. Leadership changes aim to enhance Inogen's strategic goals in respiratory care. Future performance remains uncertain due to market risks and competition.

Inogen, Inc. (NASDAQ: INGN) announced that its presentation at the 40th Annual J.P. Morgan Healthcare Conference has been rescheduled to a virtual format. President and CEO Nabil Shabshab will present on January 12, 2022, at 10:30 a.m. ET. Interested investors can access the live audio webcast through the Investor Relations section on the Inogen website. A replay will be available shortly after the live event for 90 days. Inogen specializes in developing and marketing portable oxygen concentrators for patients with chronic respiratory conditions.

Inogen, Inc. (NASDAQ: INGN), a medical technology firm specializing in respiratory products, announced participation in the 40th Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab is set to present on January 12, 2022, at 10:30 a.m. PT. The live audio webcast will be accessible via the Investor Relations section of Inogen's website. A replay will be available for 90 days post-event. Inogen continues to utilize its Investor Relations platform for disclosing material non-public information.

Inogen, Inc. (NASDAQ: INGN) has appointed Mike Sergesketter as Interim Chief Financial Officer, effective immediately. He succeeds Alison Bauerlein, who will remain in a transitional role until the end of Q1 2022. Sergesketter brings over 40 years of finance experience, having previously served as CFO at Kimball Electronics, where he facilitated globalization strategies. Nabil Shabshab, CEO of Inogen, expressed confidence in Sergesketter’s ability to support the company's strategic evolution in respiratory care.